Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
223
-
Total 13F shares, excl. options
-
68.6M
-
Shares change
-
+781K
-
Total reported value, excl. options
-
$2.75B
-
Value change
-
+$26.1M
-
Put/Call ratio
-
1.03
-
Number of buys
-
117
-
Number of sells
-
-100
-
Price
-
$40.10
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q1 2023
264 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q1 2023.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 223 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 68.6M shares
of 96M outstanding shares and own 71.53% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (6.75M shares), WELLINGTON MANAGEMENT GROUP LLP (5.1M shares), BlackRock Inc. (4.87M shares), RTW INVESTMENTS, LP (4.27M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.54M shares), STATE STREET CORP (2.75M shares), Clearbridge Investments, LLC (2.7M shares), FEDERATED HERMES, INC. (2.53M shares), Avidity Partners Management LP (2.13M shares), and ALKEON CAPITAL MANAGEMENT LLC (1.85M shares).
This table shows the top 223 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.